Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial -

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Neurological disorders
Summary
RCT (n=1466) reported that at 2 h postdose, rimegepant, an investigational calcitonin gene-related peptide receptor antagonist, was superior to placebo for freedom from pain (21% vs 11%, p<0.0001) and freedom from the most bothersome symptom (35% vs 27%, p=0.0009).
UKMi comment
A related commentary discusses the results of this trial in the context of emerging novel migraine treatments targeted toward calcitonin gene-related peptide mechanisms.
Related links: Comment